Back to results
US 12,298,304 B2Granted
Compositions and methods for diagnosing and assessing rheumatoid arthritis
AssigneeInova Diagnostics, Inc.
InventorMichael Mahler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of anti-PAD IgA as a clinical biomarker for diagnostic and prognostic information in rheumatoid arthritis (RA) patients. The disclosure further provides methods and compositions for the detection anti-PAD IgA in a biological sample.
Claims16
One or more detection kits comprising:
- (a) a peptidyl arginine deiminase 4 (PAD4) or antigenic fragment thereof;
- (b) a first antibody or functional fragment thereof capable of binding to anti-PAD4 IgA;
- (c) a second antibody or functional fragment thereof capable of binding to anti-PAD4 IgG;
- (d) a solid support;
- and
- (e) a peptidyl arginine deiminase 1 (PAD1) or antigenic fragment thereof;
- wherein the one or more detection kits are used usable in the a method for assessing disease severity in a subject having rheumatoid arthritis (RA);
- and
- wherein a severity of the RA is based on presence of joint erosion or severe joint erosion in the subject.
6 more elements
A detection kit comprising:
- (a) a peptidyl arginine deiminase 4 (PAD4) and a peptidyl arginine deiminase (PAD1) or antigenic fragments of PAD4 and PAD1;
- (b) two or more antibodies or functional fragments thereof, wherein a first antibody or functional fragment thereof is capable of binding to anti-PAD4 IgA and a second antibody or functional fragment thereof is capable of binding to anti-PAD4 IgG;
- and
- (c) a solid support;
- wherein the detection kit is usable in a method for assessing disease severity in a subject having rheumatoid arthritis (RA), and wherein a severity of the RA is based on a presence of joint erosion or severe joint erosion in the subject.
2 more elements
Dependencies are inferred from the claim text.